



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, 14/72, A61K 38/04, A61P 15/06, G01N 33/50, 33/68		A1	(11) International Publication Number: WO 00/17348								
		(43) International Publication Date: 30 March 2000 (30.03.00)									
(21) International Application Number: PCT/CA99/00844		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).									
(22) International Filing Date: 15 September 1999 (15.09.99)											
(30) Priority Data: 09/154,627 17 September 1998 (17.09.98) US											
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/154,627 (CIP) Filed on 17 September 1998 (17.09.98)											
(71) Applicant (for all designated States except US): HOPITAL SAINTÉ-JUSTINE [CA/CA]; 3175 Côte Sainte-Catherine, Montréal, Québec H3T 1C5 (CA).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>									
(72) Inventors; and (75) Inventors/Applicants (for US only): CHEMTOB, Sylvain [CA/CA]; 6885 Banting, Montréal, Québec H4W 1G1 (CA). PERI, Krishna, G. [CA/CA]; #315, 3555 Atwater Avenue, Montréal, Québec H3H 1Y3 (CA).											
(74) Agents: CÔTÉ, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).											
(54) Title: <u>G PROTEIN-COUPLED RECEPTOR AGONISTS OR ANTAGONISTS</u>											
(57) Abstract											
<p>The present invention relates to a new class of G protein-coupled receptor agonist or antagonist, which specifically binds to the receptor protein structural elements, thus altering signal transmission and subsequent physiological effects. Described herein are peptide sequences derived from the G protein-coupled receptor protein, produced by chemical methods as selective inhibitors of signal transduction associated with stimulation of the receptor by its ligand. Such peptides or molecules derived from their primary, secondary or tertiary structures may be used as effective tocolytics for the prevention of premature labor or be used for the treatment of dysmenorrhea.</p>											
<table border="1"> <caption>Fold stimulation of IP hydrolysis</caption> <thead> <tr> <th>Treatment</th> <th>Fold stimulation of IP hydrolysis</th> </tr> </thead> <tbody> <tr> <td>Vehicle</td> <td>~20</td> </tr> <tr> <td>PCP-8</td> <td>~10</td> </tr> <tr> <td>PCP-10</td> <td>~9</td> </tr> </tbody> </table> <p>100 μM</p>				Treatment	Fold stimulation of IP hydrolysis	Vehicle	~20	PCP-8	~10	PCP-10	~9
Treatment	Fold stimulation of IP hydrolysis										
Vehicle	~20										
PCP-8	~10										
PCP-10	~9										